Summary
Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effecting cell death. Monoclonal antibodies (or their fragments) have been most commonly used to carry chemically conjugated toxins to proteins or antigens overexposed on the tumor cell surface, but specific ligands for tumor cell surface receptors could also provide effective targeting.
The receptor for epidermal growth factor (EGFR) is overexpressed primarily in poor prognosis breast cancers that do not respond well to traditional therapies. Because EGFR is frequently overexpressed in breast cancer tissue and is associated with a poor prognosis, it is an attractive target for antitumor therapy.
DAB 389 EGF is an EGFR specific fusion toxin produced with recombinant DNA techniques consisting of sequences for the enzymatically active and membrane translocation domains of diphtheria toxin plus sequences for human epidermal growth factor. DAB 389 EGF is a potent, EGFR specific, cytotoxic agent which rapidly inhibits protein synthesis by a mechanism of action similar to that of diphtheria itself. Preclinical studies in the laboratory and in animals now suggest the feasibility of investigating such an agent in the targeted therapy of patients with human breast cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Vallera DA: Immunotoxins: Will their clinical promise be fulfilled? Blood 83:309–317, 1994
Frankel A: Immunotoxin therapy of cancer. Oncology 7(5):69–98, 1993
Grossbard ML, O'Day S, Gribben JG, Freedman AS, Rabinowe SN, Newbey D, Esseltine DL, Epstein CL, Nadler LM: Anti-B4-blocked ricin therapy following autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: Update of Phase I/II trials. Blood 82:444a, 1993
LeMaistre CF, Meneghetti C, Rosenblum M, et al: Phase I trial of an IL-2 fusion toxin in hematologic malignancies. Blood 79:2547–2554, 1992
LeMaistre CF, Craig FE, Meneghetti C, et al: Phase I trial of a 90 minute infusion of the fusion toxin DAB 486 IL-2 in hematologic cancers. Cancer Res 53:3930–3934, 1993
Smith JA, Barraclough R, Gernig DG, Rudland PS: Identification of alpha transforming growth factor as a possible local trophic agent for the mammary gland. J Cell Physiol 141:362–370, 1989
Snedeker SM, Brown CF, DiAugustine RP: Expression and functional properties of transforming growth factor alpha and epidermal growth factor during mouse mammary gland ductal morphogenesis. Proc Natl Acad Sci USA 88:276–280, 1991
Osborne CK, Hamilton B, Titus G, Livingston RB: Epidermal growth factor stimulation of human breast cancer cells in tissue culture. Cancer Res 40:2362–2366, 1980
Arteaga CL, Coronado E, Osborne CK: Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2:1064–1069, 1988
Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398–1402, 1987
Oka T, Tsutsumi O, Kurachi H, Okamoto S: The role of epidermal growth factor in normal and neoplastic growth of mouse mammary epithelial cells.In: Lippman ME, Dickson RB (eds) Breast Cancer. Cellular and Molecular Biology. Kluwer Academic Publishers, Boston, 1988, pp 343–362
Glenney JR Jr, Chen WS, Lazar CS, Walton GM, Zokas ML, Rosenfeld MG, Gill GN: Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of antiphosphotyrosine antibodies. Cell 52:675–684, 1988
Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1:216–223, 1987
Reddy DB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK: Inhibition of breast cancer cell growthin vitro by a tyrosine kinase inhibitor. Cancer Res 52:3636–3641, 1992
Falette N, Lefebvre M-F, Meggouh F, Eynard M, Garin E, Saez S: Measurement of occupied and non-occupied epidermal growth factor receptor sites in 216 human breast cancer biopsies. Breast Cancer Res Treat, in press
Nicholson S, Halcrow P, Sainsbury JRC, Angus B, Chambers P, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFR) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58:810–814, 1988
LeMaistre CF, Rosen S, Frankel A, et al: Phase I trial of H-65 RTA in patients with cutaneous T-cell lymphoma. Blood 78:1173–1182, 1991
Spitler LE: Clinical studies: Solid tumors.In: Frankel AE (ed) Immunotoxins. Kluwer Academic Publishers, Boston, 1988, pp 493–515
Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW, Scannon PJ: Phase I study of monoclonal antibody-ricin A chain immunotoxin Xomazyme-791 in patients with metastatic colon cancer. Cancer Res 49:6153–6160, 1989
Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE: Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxin effect not predicted by animal studies. J Natl Cancer Inst 81:775–781, 1989
Nadler L, Beitmeyer J, Grossbard M, et al: Anti-B2 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of 7 day continuous infusion. Blood 76:364, 1990
Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052–4058, 1991
Shaw JP, Akiyoshi DE, Arrigo DA, Rhoad AE, Sullivan B, Thomas J, Genbauffe FS, Bacha P, Nichols JC: Cytotoxic properties of DAB 486 EGF and DAB 389 EGF, EGF receptor targeted fusion toxins. J Biol Chem 266:21118–21124, 1991
Shaw JP, Arrigo DA, Cleveland MM, et al: Epidermal growth factor mediated binding, internalization and cytotoxicity of the fusion toxin DAB 389 EGF. Proc AACR 33:3114, 1992
LeMaistre F, Deisseroth A, Fogel B, et al: Phase I trial of H65-RTA in patients with chronic lymphocytic leukemia. Blood 26:295 (abs), 1990
Hertler AA, Schlossman DM, Borowitz MJ: A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod 7:97–113, 1988
Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW II, Longo DL, Gould B, Frankel A, McClay EF, Howell S, Reed E, Willingham MC, Fitzgerald DJ, Pastan I: Clinical evaluation of intraperitonealPseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9:2095–2103, 1991
Bookman M, Godfrey S, Padavil K, et al: Antitransferrin receptor immunotoxin therapy: Phase I intraperitoneal trial. Proc Am Soc Clin Oncol 9:187, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LeMaistre, C.F., Meneghetti, C., Howes, L. et al. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Tr 32, 97–103 (1994). https://doi.org/10.1007/BF00666210
Issue Date:
DOI: https://doi.org/10.1007/BF00666210